- 來源： CentryMed
- 作者： CentryMed
-
2025.08.28
On August 21, 2025, at the BioSeedin Annual Meeting, discussions on innovative drugs in China were full of confidence and strength. Words that once shrouded the industry, such as' winter 'and' involution ', are quietly fading away, replaced by new keywords such as' value', 'going global', and 'innovation'. When multinational pharmaceutical companies (MNCs) cast a vote of trust in Chinese innovative drugs with real money and frequent overseas transactions, China is becoming a global source of new drug research and development. This is not only a high recognition of China's innovative drug research and development capabilities, but also an important step taken by Chinese pharmaceutical companies in global competition.
At the same time, the capital market has keenly captured this positive signal, with the stock price of the innovative pharmaceutical sector rising and investment enthusiasm significantly recovering, injecting strong momentum into the industry's development. Different from the past foam growth, this round of recovery is driven by innovative value, and it moves forward steadily with the rationality and tenacity precipitated in the "cold winter". Numerous Chinese innovative pharmaceutical companies are moving towards the world with a more open and confident attitude, writing their own shining moments!
Part1
Emerging Target Forum（08.21AM)
Guest speeches and roundtable discussions
Niu Zhangming, Founder&CEO of Delight Medicine
Niu Zhangming, founder and CEO of DeRui Pharmaceutical, shared the application of AI in the field of new drug development and introduced the DeRui AI pharmaceutical platform: Traditional new drug development often relies on "luck", while generative AI has had a significant impact on the field of life sciences, greatly accelerating the development of biomedicine. The Derui AI Pharmaceutical Platform is a one-stop platform driven by a large language model, which can complete target and mechanism discovery/confirmation, information extraction and cleaning, and customized project database construction, enabling precise and customized drug design.
Wu Haiping, Sai Lan Pharmaceutical, CEO
Subsequently, Wu Haiping, CEO of Sailan Pharmaceutical, elaborated on the significant value of epigenetics in drug development and Sailan Pharmaceutical's related drug development platform: epigenetic regulation is a key marker of tumors, forming a "synthetic lethality" with other features. Epigenetic regulation is an important factor and modifiable target in tumor progression. Sailan Pharmaceutical has an innovative epigenetic drug development platform, and multiple innovative tumor drug products have entered clinical trials through related pipelines. Epigenetic drugs have achieved success in the development of hematological malignancies and are moving towards greater market opportunities in solid tumor development.
Zhuge Xin, Director of Process Development Department at Zhixiang Biotechnology
Zhuge Xin, Director of the Process Development Department at Zhixiang Biotechnology, shared how efficient process development strategies can empower clinical and commercialization: from a production cost perspective, most innovative pharmaceutical companies are unable to achieve profit conversion from clinical development to commercial sales of their products. By increasing production/yield/shortening process time/reducing process complexity, process matching scalability and selecting appropriate production scaling, promoting stable domestic supply chains, actively matching automation/intelligence of processes, and designing scientifically reasonable technology transfer methods, it is essential to empower clinical and commercialization. Zhixiang Biotechnology provides a series of effective strategies for achieving efficient process development.
Song Wenxin, Deputy General Manager of Minwei Biotechnology
Song Wenxin, Vice General Manager of Minwei Biology, shared the target pairing strategy in the design of GLP-1 multi-target drugs related to weight loss: the three core aspects of drug weight loss include reducing energy intake, increasing energy expenditure, and rapidly mobilizing fat. If weight loss drugs only suppress appetite, they will bring a series of problems, such as significant low calorie intake leading to muscle loss, so it is necessary to balance the three core indicators. In the design of multi-target drug combinations, GLP-1 and GIP are the cornerstone of weight loss drugs, while GCG, Amlin, PYY, anti ActRII, and others are optional targets.
The roundtable discussion was chaired by Lu Hongtao, co-founder and CSO of Kewang Pharmaceutical. Guo Jiacong, Executive Director of Boyuan Capital, Zhao Xinhao, VP of CICC Capital and head of the medical department of CICC Jiangsu Fund, Hu Xiaobin, Senior Director of Boehringer Ingelheim Risk Fund, and Jiang Hua, Executive Director of Business Development of BeiGene, jointly discussed the "new target project proposal for going global and BD needs from the source".
Panel photo
Round table guests believe that China, with its continuous attention to cutting-edge targets, significant achievements in target combination innovation, and continuously improving research and development capabilities, is becoming a key growth pole in the global pharmaceutical innovation landscape. During the discussion, it was emphasized that breakthroughs in key technologies have injected strong momentum into the industry. The deep application of AI and big data will have a disruptive impact on drug development, especially in the research and development of nucleic acid drugs and peptide drugs, which are expected to achieve significant breakthroughs. The blood-brain barrier related drug field continues to demonstrate blue ocean potential.
The guest pointed out that the Chinese pharmaceutical industry is steadily improving its ability to withstand research and development risks, and achieving synergy between First in Class and Best in Class in pipeline layout. Although promoting innovative target research and development requires a necessary process, practice has shown that the development of best in class drugs often leads to First in class achievements. The deepening of technological innovation and target combination innovation will continue to drive this evolutionary process forward, and China is firmly committed to this path. At the same time, the guests are full of confidence in the breakthroughs in the research and development of China's First in Class drugs and their prospects for going global.
Regarding innovative practices, guests suggest that companies should uphold a spirit of perseverance and a pragmatic attitude, pay attention to resource integration and strategic control in the innovation process, in order to better seize industry opportunities and promote high-quality development of pharmaceutical innovation.
Part2
Antibody Immunogenicity and PK Forum（8.21AM)
Guest speeches and roundtable discussions
Wei Guolan, Lai Boke
Director of Labcorp APAC Bioanalytical
Director of Labcorp APAC Bioanalytical, Wei Guolan, gave a speech on the topic of "Regulatory and Scientific Considerations for ADC Bioanalysis", mainly focusing on Challenges in bioanalytical assay development, Assess and develop DAR-insensitive ADC assay, Hybrid LC/MS vs. ligand binding assay Exciting introductions were made in several aspects.
Qin Qiuping,Shanghai Institute of Materia Medica,
Chinese Academy of Sciences Chief Scientist of Drug Safety Evaluation Research Center
Qin Qiuping, the chief scientist of the Chinese Academy of Sciences Shanghai Institute of Materia Medica and the Center for Drug Safety Evaluation and Research, shared a speech on the theme of "Non clinical PK bioanalysis strategy for bispecific antibody drugs", and introduced the development strategy of PK bioanalysis methods from the general considerations of its reaction mechanism, structural characteristics of bispecific antibodies, in vivo biology, dosage and validation of analytical methods.
Dong Zhicheng,ACRO Biosystems
Product Manager of CMC Platform Product Development Division
ACRO Biosystems' Dong Zhicheng gave a speech on the topic of "Addressing Challenges in Antibody Drug Conjugate Development". He mainly introduced the corresponding solutions that Acro can provide from the perspectives of ADC research and development hotspots, antibody affinity optimization, DAR value consistency, etc., including endocytosis detection reagents, different surface plasmon resonance (SPR) detection methods, and excellent products and services such as site-specific coupling achieved through polysaccharide modification.
Zhao Juan, Vice Director of Bioanalytical Technology at Kangweixun Biotechnology
Zhao Juan from Kangweixun Biotechnology gave a speech on the topic of "Application of Universal PK and Universal ADA Methods in Preclinical Drug Development", introducing the application of universal PK platform in ADC project and comparing universal PK method and target specific method; And the universal ADA method was introduced, which has a short cycle, can achieve rapid detection, and is suitable for multiple genera and subtypes of antibodies. The universal ADA method was compared with the conventional ADA method (bridging method).
The roundtable was chaired by Zou Linglong, founder, chairman, and CEO of Kangweixun Biotechnology. David Sun, Senior Vice President of Clinical at Hankou Biotechnology, Zhang Erhui, Senior Director of Hanlin at Fosun Pharma, Huang Liang, Director of Clinical Pharmacology at Yiming Anke, Pan Zhaoxuan, Senior Manager of Clinical Pharmacology at Arno Biotech, and Wei Guolan, Director of APAC Bioanalytical Bioanalytical at Labcorp, jointly discussed the topic of "Immunogenicity of Biopharmaceuticals and Common Risks and Clinical Value Impact of PK Data"
Panel photo
The guests shared different challenges in biological analysis. There are significant differences between PK in basic research and clinical applications; The delay of PD is also a very important point. Bioanalysis is crucial for approval by institutions such as the FDA, taking into account both clinical and methodological advantages and disadvantages, specificity, and interference. Evaluation of immunogenicity during the marketing phase of drugs. The difficulty of predicting clinical data, including the volume of sampling, and so on.
Part3
Solid Tumor Immune Cell Breakthrough Forum（8.21AM)
Guest speeches and roundtable discussions
Li Yi, Chairman of Wansheng Biotechnology CSO
Li Yi from Wansheng Biotechnology will first share the theme of "In vivo redirection of T cells - a highly accessible and effective" spot type "TCR-T therapy". Through the introduction of the technical principles of two different technological paths and the combination of multiple cases, it is shown that protein induced in vivo CAR-T can achieve clinical effects that ex vivo products cannot achieve. It is easier to control and adjust in clinical practice, and after optimizing the affinity of the target antigen, TCR-T has shown significant advantages and good safety.
Jiang Zhenggang，Partner of Yimufeng Biotechnology
SVP、Head of Strategic Center
The speech by Jiang Zhenggang from Yimufeng Biotechnology was themed "A novel lentiviral based platform for In Vivo CAR-T generation". Through multiple practical cases of In Vivo CAR-T, it was demonstrated that in vivo CAR-T based on lentivirus exhibited multiple advantages, especially XG pseudotyped lentivirus. Compared with traditional VSV-G, it showed significant advantages in titer, specificity, and killing activity, and improved yield and infection efficiency.
Yu Chen，ACRO Biosystems Product Manager
of CMCProduct Development Division
ACRO Biosystems gave a speech on the topic of "Research Progress and Application of Efficient Amplification Technology for Gamma Delta T/MSC Cells" in the morning. Firstly, focusing on the immune cell culture scheme, ACRO has achieved a multi-source, multi process, and multi-directional culture path based on core basic culture medium products, combined with multiple culture differentiation factors, forming a solution that covers the needs of the entire culture direction. In terms of stem cell culture, ACRO provides a complete solution from the initial adhesion stage to pre-treatment factors and culture medium, empowering the entire process of cell therapy.
Jinhua Jun, Jun Sai Biology, CEO/CTO
The theme of the speech by Jinhua Jun, CEO of Junsai Biology, is "Innovation and Breakthrough in TIL Treatment of Solid Tumors". The content analyzes the unresolved pain points of traditional TIL in current clinical practice and proposes innovative improvement plans that are not dependent on IL-2. Currently, a large amount of clinical research data has shown the effectiveness and safety of this plan. In the future, disruptive innovative technologies will have significant implications for clinical treatment guidance.
The roundtable discussion was chaired by Wang Liqun, founder, chairman, and CEO of Xingyiang, Li Yi, chairman and CSO of Wansheng Biotechnology, Jinhua Jun, CEO/CTO of Junsai Biotechnology, and partner of Yimufeng Biotechnology, SVP、 Jiang Zhenggang, the head of the Strategic Center, jointly discussed "When and how will the breakthrough in solid tumors once again ignite the wave of immune cell therapy.
Panel photo
The guests believe that immune cell therapy, as an important direction in the biomedical field, has undeniable significance. The current industry is exploring the role of immune cells in different fields through technological innovations such as genetic modification, while ensuring safety remains a core concern. Although immune cell therapy is still in its early stages of development, its potential is enormous, and future popularization needs to be based on safety and continuously validated for effectiveness. At the same time, cost is also a key factor in the development of the industry. Reducing treatment costs through technological innovation will provide important guarantees for the widespread application of immune cell therapy. Overall, immune cell therapy is in the stage of exploration and rapid development, and continuous innovation and research in the industry are the fundamental driving force for the diversified development of CGT field.
Part4
Neurology Roadshow（8.21AM)
Guest speeches and roundtable discussions
In this roundtable discussion, chaired by Hu Hongdan, Executive Director of Jifeng Capital, Shen Huaqiong, Founder and CEO of Neogene Pharmaceuticals, Liu Weimin, Managing Director of BeiGene Biotech Venture Capital, Yu Bingke, General Manager of Fosun Pharma's External Innovation Department, and Shen Jiong, Managing Partner of Fengrui Capital, we discussed the topic of "Don Quixote: How Biotech Challenges CNS Challenges"? ”.
Panel photo
The roundtable guests pointed out that although CNS is the world's second largest drug research and development field, China's development in this field still lags significantly behind popular directions such as oncology. The main reasons include high clinical development risks, low conversion success rates, capital preference for stable returns, and a lack of source innovation capabilities and related talents domestically. At the same time, it is emphasized to select validated targets, focus on unmet clinical needs, and reduce research and development risks through cross-border cooperation. Finally, the attendees called on the industry to focus on scientific research, strengthen talent cultivation, utilize China's abundant clinical resources to promote first in class innovation, and ultimately develop CNS new drugs that can go global.
Yuan Jun, Ideals， Global Vice President&Head of East Asia Region
Against the backdrop of a severe financing environment, complex due diligence processes, and high data compliance requirements, biopharmaceutical companies are facing multiple challenges. Ideals Virtual Data Room (VDR), as a professional and secure information management platform, is increasingly becoming an indispensable core tool for enterprises in cross-border financing, mergers and acquisitions, and strategic cooperation. Through strict permission control, operational auditing, and leak prevention mechanisms, VDR not only significantly improves due diligence and trading efficiency, but also wins the trust of investors with transparent and trustworthy data management.
Ma Weiwei, Zhuokai Biotechnology, General Manager
Zhuokai Biotechnology focuses on the research and development of innovative drugs for central nervous system diseases, founded by Professor Zhong Yi from Tsinghua University. The company focuses on unmet clinical needs such as Alzheimer's disease, pioneering a new therapeutic concept targeting the "forgetting mechanism", and developing the world's first Rac1 small molecule inhibitor 50561. This drug directly improves the core symptoms of AD by inhibiting excessive forgetting of key targets, and its small molecule form significantly reduces treatment costs. At present, the Phase IIa clinical trial of 50561 for the treatment of mild to moderate AD has been completed and enrolled. It is expected to release the top line data in the fourth quarter of 2025 and actively prepare for Phase III clinical trials. The company is simultaneously advancing multiple early pipelines and continuously exploring new therapies for neurodegenerative diseases.
Wang Junyi, Head of BD at Zhengda Fenghai Pharmaceutical
Zhengda Fenghai Pharmaceutical is an innovative pharmaceutical company focused on the treatment of neurological diseases, with a CADD/AIDD computer-aided drug design platform. The core pipeline FHND1002 is a First in Class neural regeneration and neuroprotective molecule, which has multiple mechanisms such as promoting the degradation of erroneous proteins, axonal regeneration, and improving glial cell function. Preclinical data indicate that it is involved in stroke ALS、 Significant improvements in motor and cognitive function were observed in models such as Parkinson's disease, and phase I clinical trials demonstrated good safety and pharmacokinetic properties.
Shen Huaqiong, Founder and CEO of New Oushen Pharmaceutical
NewOcean Pharmaceuticals focuses on innovative therapies for central nervous system diseases and has established research and development centers in both China and the United States. The company relies on the AI driven small molecule discovery platform (NeuChime) ?）， Build a global pipeline covering diseases such as epilepsy, depression, and schizophrenia. The core products NS-041 and NS-136 have both entered Phase II clinical trials, with NS-136 targeting the needs of elderly patients with better safety. Simultaneously developing the non hallucinogenic antidepressant drug NS-079. The company has completed the Pre-A and Series A financing rounds and is actively promoting global cooperation, striving to become an international leading biotechnology enterprise in the CNS field.
Sun Qifeng, Chief Operating Officer of Ruichu Pharmaceutical
Ruichu Pharmaceutical is a rare new drug research and development enterprise in China that focuses on anti-aging mechanisms. With cellular aging biology as its core, it has laid out multiple technological routes such as clearing, activating, and reversing aging cells. The company focuses on age-related diseases such as neurodegenerative diseases. Its core product RC007 works by activating autophagy and inhibiting inflammation through dual mechanisms, significantly improving neurological function damage in animal models such as stroke and Parkinson's disease, demonstrating the potential for multi indication expansion. The team is led by multiple Nobel laureates and senior experts, and two core pipelines are expected to achieve clinical applications for both China and the United States in the fourth quarter of 2025, committed to breaking through the treatment dilemma of age-related diseases from the perspective of aging biology.
Huang Mingyue, Chairman of Baiyi Biotechnology
Baiyi Biotechnology focuses on the research and development of breakthrough migraine drugs. With its internationally leading ExchaBody technology platform, the company has built a globally leading pipeline of innovative macromolecular drugs. Its core product BY002 is an innovative "dual target" nanobody, which is small in size and can accurately target targets that traditional drugs cannot reach. Preclinical studies have shown that BY002 has a fast onset, strong efficacy, and long duration, while demonstrating excellent safety. The production process and quality control have both met the application standards, and clinical research is planned to be promoted by 2026. Baiyi Biotechnology has multiple new generation antibody drugs under development, which will continue to bring innovative therapies to migraine patients.
Part5
Antibody Discovery Forum（8.21PM)
Guest speeches and roundtable discussions
Teng Yumin, Sai'er Nabo, CEO
Teng Yumin, CEO of Sail Nano, gave a speech on the application of nanobodies under the trend of new antibodies, reviewing the discovery process and development direction of nanobodies. She pointed out that nanobodies have the advantages of strong tissue penetration, uniform distribution in vivo, and the ability to achieve surface drug delivery, and have broad market prospects. Sai'ernabo has broken through patent barriers and built a genetically modified mouse innovation platform that integrates core technologies such as rapid construction, strong immune response, and TFP universal purification.
Su Zhipeng, R&D Director of Rongjiekang Biotechnology
Su Zhipeng, the R&D Director of Rongjiekang Biotechnology, shared his insights on the use of artificial intelligence in the development of single domain antibody drugs. He stated that drug development is a lengthy process that requires significant investment, and the design and optimization of AI can significantly accelerate drug development cycles and reduce R&D costs. Through data mining, model training, and other methods, AI can provide more accurate decision-making for drug development.
Yu Haijia, Director of Huabo Biology
Yu Haijia from Huabo Biotechnology gave a speech on the pharmacological evaluation of self immune dual antibodies. Firstly, it was introduced that there is a huge population of self exempt disease patients and a huge market potential. There are many challenges in the pharmacological research of dual antibodies, which are generally divided into three categories: in vitro pharmacological evaluation, in vivo pharmacological evaluation, and CMC stage pharmacological evaluation. And taking the company's self-developed dual resistance TSLP and IL-11 as examples, the evaluation method for dual resistance drug development was introduced.
Zhang Yanfeng, Co founder and President of AlaMab Therapeutics
Zhang Yanfeng, President of AlaMab Therapeutics, shared the role and research progress of the innovative target Connexin43 half channel in neurological and bone related diseases. In his speech, he highlighted the team's progress in bone cancer-related research, particularly in the study of the CXC43 protein half channel. This half channel mainly mediates the exchange of substances inside and outside the cell, and plays an important role in the occurrence and development of neuroinflammation and cancer. In addition, Dr. Zhang also mentioned the team's preclinical and clinical research in the fields of acute spinal cord injury, osteoarthritis, and metastatic bone cancer.
Xiaozuo Xiang, Chairman and General Manager of Shimai Pharmaceutical
Xiao Zuoxiang, Chairman and General Manager of Shimai Pharmaceutical, gave a speech on early antibody discovery strategies and prospects. Shared the development process of China's innovative drug field, especially the phenomenon of antibody drugs going global, indicating that China's innovative drugs are gradually gaining international recognition. At the same time, key technologies for improving antibody discovery efficiency were introduced, such as single-cell antibody screening and high-throughput screening methods, which can quickly produce a large number of required antibodies. Finally, the guests emphasized the advantages and characteristics of different screening techniques, providing a solid foundation for antibody discovery, and looked forward to China continuing to maintain its advantages in this field and promoting innovative drugs to the world.
The roundtable discussion was chaired by Guo Bingshi, General Manager of the Biological Science Department of Jiyu Pharmaceutical. Xiao Zuoxiang, Chairman and General Manager of Shimai Pharmaceutical, Huang Haomin, Vice President of R&D at Sansheng Pharmaceutical, and He Yun, Chief Technology Officer of Nona Biotechnology, jointly discussed "What are the new requirements and trends in antibody discovery.
Panel photo
The attendees pointed out that under the promotion of platforms such as genetically modified mice, antibody discovery is showing a trend of increasingly complex molecular structures, such as the emergence of multifunctional molecules such as bispecific and tertiary antibodies, which puts higher demands on the stability and efficient production of molecules. Sansheng Pharmaceutical emphasizes that drug efficacy and clinical expectations should be the core considerations. Currently, the efficacy period of bispecific drugs is relatively short, while monoclonal antibodies still have advantages in certain indications.
The discussion also extends to the fields of non tumor and non autoimmune diseases, and it is believed that antibodies also have broad prospects in the major health markets such as medical aesthetics, weight loss, and anti-aging. Inflammation is considered an important trigger for aging and other issues, and antibodies have great potential in related interventions. In terms of the application of new technologies, attending experts remind that there is still a lot of room for exploration in biological research, and an open and pragmatic attitude should be maintained.
Finally, the diverse layouts of enterprises including Nona Biotech in the fields of oncology, hematology, nephrology, and overall health were shared, emphasizing the need to combine clinical and customer needs to promote antibody research and development to a higher level.
Part6
ADC Treatment Window Widening Strategy Forum（8.21PM)
Guest speeches and roundtable discussions
Kang Mingchao, BeiGene, Senior Director of BioDiscovery
Kang Mingchao, Senior Director of BioDiscovery at BeiGene, gave a speech on the topic of "Decision Considerations for Target and Payload Selection in ADC Project Approval". He analyzed the selection of dual target combinations, the development process of payloads, and the sources of toxicity. He shared the decision considerations for selecting new ADC payloads, the application of C-terminal coupling technology, BeiGene's ADC layout, and key decision-making logic for research and development.
Mao Yanli, Vice President/Co founder of R&D at Tuoji Pharmaceutical
Mao Yanli, Vice President/Co founder of R&D at Tuoji Pharmaceutical, gave a speech on the theme of "ADC R&D progress and differentiated project proposal strategies". He analyzed the drug characteristics of ADC from three aspects: half-life differences, killing modes, and lipid solubility. Through the introduction of the company's R&D pipeline progress, he elaborated on the drug resistance mechanism and response strategies, and proposed that finding new mechanisms for payloads is very important for R&D projects.
Yan Shuizhong, Chief Operating Officer of Global R&D at Zaiding Pharmaceutical
Yan Shuizhong, Chief Operating Officer of Global R&D at Zaiding Pharmaceutical, gave a speech titled "Reflections on the Development of New Generation ADC Drugs". Yan Bo introduced the characteristics and breakthrough routes of ADC technology iteration and updates, as well as the differences in ADC development at home and abroad. Finally, the development of a new generation of ADC drugs was elaborated, with a focus on exploring novel targets on the tumor surface, overcoming heterogeneity and drug resistance within and between tumors.
Song Hongbin, Senior Director of ADC at Xinda Group/Sherpa Biotech
Song Hongbin, Senior Director of ADC at Xinda Group/Sherpa Biotech, gave a speech on "Challenges in ADC Amplification Production and Process Validation". Mr. Song first introduced the development trend of ADC drugs and the expansion of application fields. Then, he conducted a comprehensive analysis and in-depth interpretation from the key points and technical challenges of ADC drug research and development to the amplification production and quality control of ADC drugs. Finally, he introduced Sherpa Company, which belongs to Xinda Group and focuses on ADC drug CDMO business
Cai Jiaqiang, Yilian Biotechnology, Co-CEO/CSO
Co CEO/CSO Cai Jiaqiang from Yilian Biotech gave a speech on "Exploration of Extracellular Lysis ADC Technology and Clinical Development Product Layout". Based on the limitations of traditional ADC drugs, Cai Bo focused on introducing the extracellular Lysis ADC technology developed by Yilian TAMLIN platform, which combines high water solubility, high uniformity, high in vitro and in vivo stability, and tumor tissue enrichment characteristics. Showing a wider drug treatment window compared to existing ADC technology means that the safety and efficacy range of drugs are broader, providing patients with safer and more effective treatment.
Finally, the roundtable forum hosted by Fu Quan, a partner of Longma Feng Venture Capital, became the focus. Cai Jiaqiang, Co CEO/CSO of Yilian Biotech, Yan Shuizhong, Chief Operating Officer of Global R&D at Zaiding Pharmaceutical, Mao Yanli, Vice President/Co founder of R&D at Tuoji Pharmaceutical, and Zhan Le, partner of Lianlian Health Fund, jointly discussed in depth the "core elements and cooperation hotspots of the next generation ADC".
Panel photo
The roundtable guests believe that from the past to the present, the competition in ADC research and development has become increasingly fierce. Effectiveness, homogenization competition, drug resistance, safety, and target differentiation will all be the future development path. The core elements of the next generation ADC also lie in the balanced and flawless components of antibodies, linkers, payloads, and coupling methods, which can have better resistance and safety, and achieve better clinical efficacy. Finally, we look forward to the future development trends of ADC drugs, such as novel linker payload ADCs, dual/triple antibody ADCs, and multi payload ADCs.
Part7
Key Technology Forum for Stem Cell Product Development（8.21PM)
Guest speeches and roundtable discussions
Liu Yang, Power Micro Official, CEO
Liu Yang, CEO of Power Micro, gave a presentation on the topic of "Construction of iPSC derived myocardial cell patches and regenerative therapy for heart failure". He first analyzed the current situation of cardiovascular and cerebrovascular diseases, myocardial infarction, and heart failure, and sorted out the existing treatment methods for these diseases. He systematically introduced the research progress of using iPSC derived myocardial tissue and stem cell transplantation therapy for patients with heart failure through global differentiation comparison of power micro organs.
Yan Xi, Huixin Medical Valley, VP
Yan Xi, VP of Huixin Medical Valley, gave a presentation on the theme of "Development and Clinical Practice of Cell Drugs Based on Induced Neural Stem Cell Technology". The system introduces the application of stem cell therapy in neurological diseases, with a focus on the company's use of reprogramming technology to directly induce peripheral blood cells to obtain neural stem cells (iNSCs), which can efficiently differentiate into various types of nerve cells for the development of innovative drugs and therapies for neurological diseases. Finally, the clinical research progress of using induced neural stem cell-derived dopaminergic precursor cells (iNSC DAP) from Huixin Medical Valley in the treatment of Parkinson's disease was introduced.
Jin Jun, Yuanwu Medical, President/CTO
Jin Jun, President/CTO of Yuanwu Medical, gave a presentation on the topic of "Application of Induced Pluripotent Stem Cells (iPSCs) in Regenerative Medicine". He first shared the technology and advantages of iPSCs, as well as the development history of iPSCs reprogramming technology. Subsequently, the key considerations for pharmaceutical research in cell therapy, quality standard setting, and non clinical research were introduced, and the current progress in iPSCs cell development was summarized. Finally, he introduced the preclinical research progress of Yuanwu Medical Company and its developed iPSC NCC MSC in the treatment of OA osteoarthritis.
Liao Lianming, Tuohong Kangheng Pharmaceutical CSO
In this sharing, Mr. Liao introduced the discovery of MSCs, the establishment of isolation and cultivation methods, and the naming process, and focused on sorting out the industrialization milestones of Osiris' promotion of MSC therapy that went through twists and turns and was finally approved in the United States. And mentioned the plasticity demonstrated in MSC research, the regenerative potential in ischemic models, and the accompanying naming controversy and other scientific backgrounds. In terms of application, it highlights the broad prospects of MSC in two major fields: immunosuppression and tissue regeneration promotion. Looking ahead to the future, the focus is on enhancing MSC functionality (MSC V2.0), utilizing it as a carrier, and reducing production costs. Finally, the progress of Jiangsu Tuohong Kangheng Company and its development of allogeneic umbilical cord derived MSC products in obtaining clinical trial approval for the treatment of Crohn's disease anal fistula was introduced.
Fan Jing, Founder&CEO of Hode Biotech
Huo De Biotechnology founder and CEO Fan Jing gave a presentation on the topic of "Progress and Challenges of Human iPSC Derived Cell Therapy Products in the Treatment of Neurological Diseases". Firstly, the clinical applications, administration methods, and diversity of MOA of iPSC derived functional cells were introduced. Subsequently, the system introduced the pluripotent stem cell-derived cell therapy products that have entered clinical trials worldwide, and mentioned that neural regeneration products are an important direction for the treatment of post-stroke and traumatic brain injury sequelae. Finally, the progress of Phase 1 clinical research on the treatment of post-stroke hemiplegia sequelae with iPSC derived hNPC01 injection was introduced.
The roundtable discussion was chaired by Le Wenjun, a researcher at Tongji University Affiliated Oriental Hospital. Fan Jing, CEO of Hode Biotech, Jin Jun, President/CTO of Yuanwu Medical, and Liao Lianming, CSO of Tuohong Kangheng Pharmaceutical, jointly discussed the "technical difficulties affecting stem cell applications".
Panel photo
The attending guests believe that mesenchymal stem cells (MSCs) still face significant challenges in terms of stability, consistency, source, and process, especially in the selection of indications, delivery methods, and clinical and CMC processes, which need further optimization. Meanwhile, the localization of reagents has become an important factor restricting large-scale production, and the insufficient inter batch stability of imported culture media may affect product purity and efficacy. In addition, the use of DMSO in MSC freezing process may cause adverse reactions, and the development of DMSO free freezing solutions has become a technical difficulty that the industry urgently needs to overcome.
Regarding the future of engineered MSCs, guests emphasized that research and development costs and efficacy are key. Improving efficacy can reduce costs, while innovative technologies and patents will create opportunities for international development. Large scale production remains an important bottleneck, and the stable supply of reagents, improvement of cell differentiation efficiency and purity, and control of miscellaneous cells all need to be further addressed.
In terms of technological innovation, AI and intelligent manufacturing are considered the future direction of stem cell applications. Although AI can optimize cell response and some process flows, the lack of industrial data accumulation is still the main limitation at present.
In addition, investors' focus on the stem cell field is on regulatory attitudes, clarity of indication mechanisms, and controllability of safety and effectiveness. Overall, the future of stem cell technology applications is full of potential, but breakthroughs are still needed in key areas to promote the deep integration of technology and industrialization.
Part8
Oncology Roadshow（8.21PM)
Guest speeches and roundtable discussions
In this roundtable, chaired by Xia Mingde, founder, chairman, and CEO of Innolux Pharmaceuticals, Xu Di, head of Bayer Co.Lab China, Li Fang, director of search and evaluation at Novartis China, Yuan Ning, senior vice president of business development at Sansheng Pharmaceutical, Sun Jiancheng, vice president of Xiansheng Zaiming, and head of global business development, discussed the differences in competition perception between MNC and biotech.
Panel photo
Guests believe that different pharmaceutical companies have their own focus areas and target selection, but whether it is biotechnology or MNC, they are more inclined to layout high-value, high medical demand indications. During the cooperation process, both parties need to fully understand the specific needs of the buyer, especially in terms of targeted communication and docking in terms of targets and indications. This will not only help promote cooperation, but also provide support for the future international layout of biotechnology.
In terms of balancing mature targets and innovative targets, from the buyer's perspective, relatively low-risk projects are more favored, but as long as the data is excellent enough, there is a possibility of reaching a deal regardless of which development stage it is in. From the perspective of the seller, the following factors are considered key to attracting cooperation: a solid data foundation, meeting outstanding clinical needs, meeting high-quality standards, and an efficient and smooth communication mechanism.
Party and Mass, Real Creatures, CEO
According to the introduction of the Real Biology Party, ADC drugs are rapidly becoming the cornerstone of cancer treatment, and their combined effect with immunotherapy is significant. However, there are resistance issues with existing ADCs and targeted drugs, involving mechanisms such as increased efflux and Topo-1 target mutations. The new generation Topo-1 inhibitor ZSSW-136 and novel payload platform in real life, through structural optimization, can overcome the above-mentioned drug resistance. They have high activity against both wild-type and mutant Topo-1 and higher safety, and are expected to solve the problem of existing drug resistance. Joint development is welcome.
Wei Dong, CEO of Fosun Pharma
Fosun Pharma focuses on developing innovative cytokine therapies. Among them, the IL-15 super agonist FL115 is the only IL-15 therapy that shows significant clinical efficacy in patients with advanced solid tumors when used alone. Its phase I/II clinical trial of PD1 single antibody combined therapy for solid tumors and phase II clinical trial of BCG combined therapy for non muscle invasive bladder cancer are starting. FL116 (a fusion protein of engineered IL-18 and PD1 monoclonal antibody) has demonstrated significant efficacy in PD1 resistant animal tumor models, and both have Best in Class potential.
Chen Wei, Lidi Medicine, CEO/CSO
At present, how to discover tumor specific driving mechanisms that can distinguish from normal tissues and organs in patients lacking treatment has become the forefront and most challenging field of tumor drug development. Due to the formation of acquired multi signal pathway interaction nodes by tumor cells in establishing their unique cellular homeostasis, multi-target drugs targeting this multi signal pathway can be developed to disrupt the tumor dependent cellular homeostasis and promote tumor cell death. Based on this, Lidi has established its own brand new technology platform and developed multiple clinical candidate drugs, among which the early clinical data of LIT0814 supports the concept validation of this technology.
Kong Qidi, co-founder and CEO of Zhongshan Zhiben Pharmaceutical
Unlike traditional AR-LBD targeted drugs, broad-spectrum AR degraders can effectively eliminate various pathogenic AR proteins, including AR-LBD point mutations and AR-V7 splice variants, expanding the applicable patient population from 25% to 100% and increasing market potential by four times. This project is a broad-spectrum AR molecular gel degradation agent targeting the nitrogen terminal domain (AR-NTD) of AR with First in Class potential. It can be orally used to treat drug-resistant metastatic castration resistant prostate cancer, targeting the billion dollar market. It has been submitted for pre IND and is expected to become the world's first broad-spectrum AR molecular gel degradation agent to enter clinical practice.
Shen Qiancheng, CEO of Yudao Biotechnology
As a biotechnology company specializing in the discovery of allosteric drugs, Yudao Biotech is committed to developing small molecule drugs for traditional difficult to drug targets. The company has developed a product called ALLOSTAR ? A proprietary platform based on artificial intelligence and physics principles, aimed at identifying hidden pockets on proteins and analyzing their conformational features, and developing small molecule drugs based on pocket discovery, optimization, and conformational mechanisms. Relying on ALLOSTAR ? On the platform, Yudao has built a pipeline for the development of allosteric drugs with potential "BIC, FIC" potential, mainly focusing on the fields of tumors and metabolic diseases.
Guo Ming, Chairman of Fuente Pharmaceutical
Suzhou Fuente Pharmaceutical has QQ protein induced in situ tissue reprogramming technology, which can transform cancer cells into normal cells and solve the problems of toxicity and drug resistance in traditional treatments. It has more than 50 patents in China and the United States. Its SON-DP injection is the first relevant drug to enter clinical practice in China, used for the treatment of advanced solid tumors. Both China and the United States have conducted clinical trials and are progressing smoothly. The plan is to launch in 2028-2029, and other disease pipelines have also been laid out. Financing is proposed to promote research and development.
Huang Changjiang, Chief Scientific Officer of Target Biotech
As a biopharmaceutical company focused on developing a new generation of antibody conjugated drugs for cancer, Target Biotech is driven by unmet clinical needs to develop a new generation of conjugated drugs that are both effective and safe, overcoming the limitations of traditional chemotherapy and targeted therapy, and providing patients with better treatment options. At present, the dual load ADC developed by the company has entered the early stage of CMC. This round of financing plans to raise 50 to 80 million RMB for the IND application, preclinical toxicology experiments, and early clinical development work of the first pipeline.
Zhou He, Senior Vice President of Duoyu Biotechnology
Hangzhou Duoyu Biotechnology focuses on fields related to cancer, autoimmune diseases, and inflammation, and is committed to developing the best dual functional molecules in its class, mainly PROTAC, to solve the problem of "difficult to develop drug targets". Currently, two pipelines, HPB-143 and HPB-092, have been approved for clinical use. The lead compound of the PROTAC project targeting KRAS G12D exhibited excellent targeted degradation activity, ADME characteristics, and in vitro and in vivo anti-tumor activity.
Chen Kran, Senior Vice President of Fanshi Pharmaceutical
As a biotech company specializing in immunotherapy and tumor therapy, Fanshi Pharmaceutical has continuously promoted pipeline development and established its own three dual antibody platforms in recent years. Currently, relying on the existing dual antibody platforms, it has established a diversified pipeline for highly refractory diseases. Currently, PT886, PT217, and PT199 have made the fastest progress and have all entered Phase 2 clinical trials. Among them, PT886, as a dual antibody FIC pipeline targeting Claudin 18.2/CD47, has obtained FDA orphan drug and fast channel qualification recognition. PT217, as a dual antibody targeting DLL3/CD47, has also obtained FDA two orphan drug and two fast channel qualification recognition.
Subsequently, the conference announced the Peak Breakthrough Award, Innovation Engine Award, Outstanding Organization Award, and Most Potential Roadshow Award. Thank you to the industry leaders for their contributions and support.
Peak Breakthrough Award: Luoqi Biotechnology
Innovation Engine Award: Ruifeng Biotechnology
Outstanding Organization Award: Kangweixun Biotechnology
Most Promising Roadshow Award: New Oushen Pharmaceutical
Exciting moments at the dinner party
In addition to technical reports and roadshows, over 400 one-on-one discussions ignited the spark of cooperation!
On the first day of the annual meeting, the atmosphere was lively and there were frequent exchanges and interactions. The precise one-on-one cooperation meeting (1-on-1 Meeting) achieved great success, efficiently facilitating over 400 high-quality one-on-one meetings on the first day.
The heads of business development and external cooperation departments from international giants such as Eli Lilly, Johnson&Johnson, Bayer, Roche, Novartis, Boehringer Ingelheim, MSD, Sanofi, AstraZeneca, Pierre Fabre, and representatives from leading domestic pharmaceutical companies such as Sinopharm Group, Renfu Pharmaceutical, and Jinsai Pharmaceutical, as well as the founders and CEOs of numerous promising innovative biotechnology companies, had in-depth and effective communication.
These talks focused on practical exchanges in various fields such as license in/out opportunities, joint research and development, technology platform authorization, strategic investment, and market commercialization cooperation. Representatives of participating companies all expressed that the efficient and private docking platform provided by Baisihui is extremely valuable, greatly saving communication costs and providing an excellent opportunity to discover potential partners and quickly promote project progress.
Being able to have centralized talks with so many high-quality target companies in one day is very efficient. We have discovered that several companies have high complementarity with us in pipeline layout and technology platforms, and we look forward to deeper contacts in the future, "said a BD manager from a multinational pharmaceutical company.
The founder of an innovative biotech company also exclaimed, 'It is a rare opportunity for us to have direct dialogue with these top global MNCs and domestic pharmaceutical companies, listen to their professional insights, and showcase our innovative achievements.'. I hope to open the door to cooperation at this annual meeting. ”
Tomorrow, the annual meeting will continue to bring more exciting thematic forums, project roadshows, and one-on-one conversations, allowing us to continue to pay attention to the emergence of more cooperation sparks.
